Advertisement

Topics

Cambridge Antibody Technology Company Profile

01:08 EST 14th December 2018 | BioPortfolio

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.

Location

Milstein BuildingGranta Park
Cambridge
Cambridgeshire
CB1 6GH
United Kingdom

Contact

Phone: 44 (0)1223 471 471
Fax: 44 (0)1223 471 472
Email: info@cambridgeantibody.com


News Articles [1000 Associated News Articles listed on BioPortfolio]

Absolute Antibody Opens New Facility to Support Continued Growth of its Recombinant Antibody Technology

Absolute Antibody Ltd., specialists in antibody sequencing, engineering and recombinant expression with a vision to make recombinant antibody technology accessible to all, has announced the opening of...

$195M+ #Cancer collaboration combines @Roche with antibody technology of Cambridge, MA, #startup GO Therapeutics: http://ow.ly/9D6030m56nS 

$195M+ #Cancer collaboration combines @Roche with antibody technology of Cambridge, MA, #startup GO Therapeutics: http://ow.ly/9D6030m56nS 

IONTAS Celebrates 5 Years of Antibody Discovery

Attributes ongoing success to scientific ethos, project management, and innovative research programs IONTAS Limited (IONTAS), a leader in the discovery and optimisation of ...

Roche, GO Therapeutics to Develop Antibody-Based Cancer Treatments

Roche plans to develop new cancer treatments based on antibody technology for which it has secured an exclusive worldwide license from GO Therapeutics, under a collaboration that the Cambridge, MA, st...

Cambridge Enterprise: How Apollo Therapeutics is driving forward therapeutic innovation.

Iain Thomas, Head of Life Sciences at Cambridge University’s technology transfer arm, discusses the recent launch of Apollo Therapeutics, an ambitious collaboration between AstraZeneca, GlaxoSmithK...

Cambridge Bancorp Announces Record Quarterly Earnings and Declares Dividend

CAMBRIDGE, Mass., Oct. 15, 2018 /PRNewswire/ -- Cambridge Bancorp (NASDAQ: CATC) (the "Company"), the parent of Cambridge Trust Company, today announced unaudited net income of Read more...

Cambridge Consultants, Exact Imaging to apply AI technology to detect prostate cancer

Cambridge Consultants is applying deep learning to high-resolution micro-ultrasound imaging to detect suspicious regions of tissue, enabling urologists to use additional data in their biopsy protocol....

.@PitchAtPalace returns to Cambridge Judge Business School today with a broad technology theme. Our #Cambridge business mentors are discovering innovative startups ranging from Biotech and Consumer Technology to Artificial Intelligence and Smart Cities. @

. @PitchAtPalace returns to Cambridge Judge Business School today with a broad technology theme. Our #Cambridge business mentors are discovering innovative startups ranging from Biotech and Consumer ...

PubMed Articles [1767 Associated PubMed Articles listed on BioPortfolio]

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

The antibody drug market is rapidly expanding, and various antibody engineering technologies are being developed to create antibodies that can provide better benefit to patients. Although bispecific a...

The Cambridge Social History of Modern Ireland : Edited by E.F. Biagini and M.E. Daly, Cambridge, United Kingdom and New York, NY: Cambridge University Press, 2017.

Engineering therapeutic bispecific antibodies using CrossMab technology.

Bispecific antibodies have recently gained major interest as they allow novel mechanisms-of-action and/or therapeutic applications that cannot be achieved using conventional IgG-based antibodies. A ma...

Measuring Antibody-Antigen Binding Kinetics Using Surface Plasmon Resonance.

Surface plasmon resonance (SPR) is now widely embraced as a technology for monitoring a diverse range of protein-protein interactions and is considered almost de rigueur for characterizing antibody-an...

Review of Steve Stewart-Williams's The Ape That Understood the Universe: How the Mind and Culture Evolve : (Cambridge: Cambridge University Press, 2018).

Clinical Trials [3238 Associated Clinical Trials listed on BioPortfolio]

Weight Loss for Obese Individuals With Gout

This study evaluates effect of weight loss in a group of obese patients with gouty arthritis. The study is a randomised group trial where half the patients receive intensive weight loss in...

Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response

In adult kidney transplant recipients a therapy-responder and non-responder phenotype by antibody mediated rejection will be precisely defined according to clinical and histological charac...

User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™

The primary aim of this study is to demonstrate the maintenance of healthy peri-stomal skin over a two month period in subjects who use ConvaTec Moldable Technology™ Skin Barriers as par...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

EBV positive tumor accounts for 8-9% of all gastric cancer (GC) patients. PD-1 antibody has been proved as third line therapy for PD-L1 positive gastric cancer. Previous studies showed tha...

Companies [1254 Associated Companies listed on BioPortfolio]

Cambridge Antibody Technology

Cambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong ...

Granta Park Ltd

Granta Park has established itself as the leading research park in the Cambridge sub-region. Concentrating on the life sciences it has attracted many of the foremost businesses in the field, including...

Cambridge Antibody Technology Group plc

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the charact...

Domantis Inc

Domantis Limited was launched in December 2000 by Sir Gregory Winter and Dr Ian Tomlinson of the MRC–LMB with the backing of the MRC and MVM Limited to commercialise Domain Antibody products. To dat...

Zenyth Therapeutics Limited

Zenyth Therapeutics Limited (Zenyth) is a public listed (ASX: ZTL) Australian biotechnology company primarily focused on the development and commercialisation of antibody-based therapies in the areas ...

More Information about "Cambridge Antibody Technology" on BioPortfolio

We have published hundreds of Cambridge Antibody Technology news stories on BioPortfolio along with dozens of Cambridge Antibody Technology Clinical Trials and PubMed Articles about Cambridge Antibody Technology for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambridge Antibody Technology Companies in our database. You can also find out about relevant Cambridge Antibody Technology Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record